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Abstract
The use of unlicensed and “off-label” medicines in children is widespread. Between 50-80% of the medicines
currently administered to children have neither been tested nor authorized for their use in the paediatric
population which represents approximately 25% of the whole European population. On 26 January 2007, entered
into force the European Regulation of Paediatric Medicines. It aims at the quality of research into medicines for
children but without subjecting the paediatric population to unnecessary clinical trial. This article addresses ethical
and legal issues arising from the regulation and makes recommendations for the framework conditions facilitating
the development of clinical research with children.
Introduction
The Coordination of Research on Priority Medicines for
Children (ERA-NET PRIOMEDCHILD) is a network of
research funding organisations from eleven different
European Union (EU)-member-states, initially founded
on January 1
st, 2007 for a period of three years extended
to four due to an official extension by the European
Community (EC). The network’s primary goal is to con-
tribute to the European Research Area on priority medi-
cines for children by implementing a European joint
research programme including development and innova-
tion themes [1]. ERA-NET PRIOMEDCHILD’s concern
is also to bring coherence and cooperation to national
research programmes and to establish policies on prior-
ity medicines for children research.
Setting
Between 2007 and 2010, key national and international
organisations including the European Medicine Agency
(EMA) and its Paediatric Committee (PDCO) represen-
tative members have been consulted to address research,
research funding, public-private research cooperation,
ethical and regulatory issues. A set of workshops and
meetings involving stakeholders, i.e., academic experts
from public hospitals, pharmaceutical industry’s,
insurance company’s, parent associations’ and health
authorities representatives were held. Based on expert
consultations, questionnaires sent to stakeholders and a
literature review on that topic, ERA-NET PRIOMED-
CHILD identified legal and ethical issues arising from
the European Regulation of Paediatric Medicines and
made recommendations for facilitating clinical research
with children.
Results
Obligations/Derogations for the pharmaceutical industry
and their consequences
The three legal pillars of the new Regulation [2] are i)
the adoption of incentives for industry; ii) the imple-
mentation of a mandatory Paediatric Investigation Plan
(PIP) considering all age ranges and iii) the creation of a
Paediatric Committee (PDCO). The Regulation provides
therefore strong obligations for the pharmaceutical
industry together with some rewards and incentives in
order to facilitate the development and accessibility of
medicinal products in paediatrics. Rules are different for
patent protected and off-patent medicinal products.
For new indications, new routes of administration or
new formulations of already patented products and for
the development of new medicinal products, pharmaceu-
tical companies (applicants) have to submit a PIP to the
PDCO before Marketing Authorization Application
(MAA) is submitted. The PIP binds applicants, but it
may be amended. Indeed, for products devoid of interest
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products can be requested [3] as well as “deferrals” of
initiation of paediatrics studies and/or completion for
products for which adult data are needed can be
requested for all subsets of the paediatric population. In
both cases they must be fully justified by the applicant.
For studies conducted in compliance with an agreed PIP
and if information is correctly provided, a reward of
6-month extension of the Supplementary Protection
Certificate (SPC) will be granted. Besides, the SPC exten-
sion duration may slow down the promotion of generic
formulations, thereby adding to the health costs [4].
A new type of marketing authorization - Paediatric Use
Marketing Authorisation (PUMA) - has been established
by the Regulation to stimulate the development of off-
patent products for paediatric use. If paediatric indications
and formulations - based on studies conducted in line
with a previously agreed PIP - are authorized, it is possible
for the applicant to get a PUMA approval with 10-year
market exclusivity. Moreover, community funding for stu-
dies on off-patent products under the Paediatric Research
Programme will be possible. Conversely, submitting a PIP
and producing data about the paediatric population for
off-patent products is an optional procedure.
Not many PUMAs are so far being applied for off-
patent products which represent an important part of
available medicines for the paediatricians [3]. To reduce
the prevalence of unmet need for children research,
ERA-NET PRIOMEDCHILD will recommend that
PUMA procedure should be mandatory and/or other
incentives implemented in order to stimulate the paedia-
tric registration of off-patent products for children. The
regulation should also have included obligations for
applicants regarding off-label drugs (i.e., drugs adminis-
tered for a different purpose from that studied and
reviewed for licensing) which are very commonly used
in ordinary practice. Actually, clinical research on these
products is rather complicated and the profit margin
being low, pharmaceutical companies generally do not
make off-label drugs available for children research [5].
Role of the Paediatric Committee of the EMA
The paediatric committee (PDCO) includes representa-
tives from all EU-member-states, health-care profes-
sionals, members of patients’ associations, permanent
and external experts, methodologists and ethics specia-
lists. Evaluation by the PDCO should take into consid-
eration the significant therapeutic benefits of the
proposed studies for children, the need to avoid unne-
cessary studies and delay of authorization for adult
populations. The drug safety and the monitoring of the
clinical trials involving children by an independent
safety monitoring committee is also an important issue
to consider [6,7]. PDCO is legally required to publish its
opinions and decisions on PIPs, waivers and deferrals
(commercially confidential information can be deleted).
ERA-NET PRIOMEDCHILD suggests that the PDCO’s
decision process on waivers would gain to be more
transparent. Besides PDCO’s required studies may have
to be reconsidered in terms of ethical and economical
feasibility. The involvement of all stakeholders earlier in
the process may be an opportunity.
The United-States (US) approach for paediatric author-
ization seems pragmatic and more flexible than in
Europe. Food and Drug Administration (FDA) asks to
pharmaceutical companies a complete Pediatric Develop-
ment Plan (equivalent to PIP in EU) providing any suffi-
cient safety data base from adult population. When an
off-label drug is used for a long period, US authorities
give a paediatric authorization based on i) the number of
paediatric patients already treated, ii) available efficacy
and safety data collected among a rather large paediatric
population, iii) the life duration of the off-label product
use, iv) adequate safety data base in adults. Specific and
justified studies are demanded only if those points are
not met. Interactions between FDA and EMA should
benefit from each other’s experience the priorities for
paediatric drug research being obviously set by the need
of the patients, not by market considerations [4,8-12].
Increasing responsibilities for researchers
Beneficence and responsibility go along, they are two
major and significant ethical issues to be found in the
new Regulation [2] (having better medicines for children
is a Beneficence) and in the Directive-2001/20/EC [13]
(having a reinforced protection for children involved in
clinical trials implies a higher Responsibility for the
researcher). Article 4 on “Clinical trials on minors” gives
specific rules to reinforce the protection of minors parti-
cipating to clinical research. Most of these stipulations
are related to the informed consent process. Specific
protection of minors implies strengthened protection
and possibly strengthened legal sanctions. Some coun-
tries sanction researchers who fail to obtain the
informed consent (see article L. 1126-1 of the French
Law “Code de la Santé Publique” [14] providing a three-
year jail term for infringement of the consent proce-
dure). From a legal point of view, the patient’sc o n s e n t
(and/or that of his/her legal representative for minors)
to participate is mandatory. Nevertheless the consent
form does not prevent the researcher from civil prosecu-
tion if a child is subjected to damage during a clinical
research. For vulnerable people, an objective civil liabi-
lity is recognized by many European legal courts [15].
From informed consent to shared consent
The informed consent should be obtained by respecting
the autonomy principle, i.e., giving complete and
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legal representative for a minor) allowing him/her to
take a free decision. Many parents openly admit that the
informed consent process is useful, albeit often confus-
ing. They find discussions more helpful than the consent
documents [16]. The decision for trial participation is
influenced by parental, child, trial and physician factors
[17]. Families can also - and often do - ask their general
practitioner, relatives or various people for advice [18].
While collecting the written consent in the case of vul-
nerable people, the Whereas 4 of the Directive-2001/20/
EC [13] draws attention to the treating doctor’sc o o p -
eration “the written consent of the patient’s legal repre-
sentative, given in cooperation with the treating doctor,
is necessary before participation in any such clinical.” So
far, the role of the treating doctor seems underestimated
o ri g n o r e da n dm o r ea t t e n t i o ns h o u l db ep a i dt od e f i n e
his/her specific role to reinforce the protection of
vulnerable subjects. Researchers should build better rela-
tionships with paediatricians/family doctors [18,19].
Even a tricky concept to apply in practice, concomitant
oral information by an independent trustworthy physi-
cian chosen by the family may be an opportunity for
substantially improving parental understanding of the
particular benefits, risks and alternatives of a trial. Pro-
viding enough time to come to the decision of consent
[20,21] is also part of the precautionary principle [22].
A pragmatic approach for assent
Despite the mandatory direct participation of children in
a shared-consent procedure, in most cases consent is
obtained after discussions with and agreement of par-
ents only while the children view point is often not
taken into account [23]. The neonate population repre-
sents the most vulnerable of all paediatric age groups
and requires even more careful review [24]. The defini-
tion of the age of consent is a controversial topic.
Important discrepancies on the consent/assent process
exist among EU-member-states [25,26]. Wendler [27]
recommends that until instruments are developed to
assess the assent capacity of individual children (ability
to understand the research in question), 14 should be
the threshold age for assent. The Ethics Working Group
of the Confederation of European Specialists in Paedia-
trics [28] considers that the ability to understand the
aim, possible benefits and risks of a research study can
be expected at the earliest from the age of 9 onward.
Yet, one must remember that the age for criminal liabil-
ities is 7 in Switzerland, 11 in the United Kingdom and
14 in Italy. In some extent it sounds such as a paradox
that minors of the same ages in one country can be
recognized as criminals but could not have their assent
taken into account for clinical trial. To conclude on this
controversial issue, we strongly recommend referring to
the Oviedo Convention Additional Protocol stipulation,
i.e., “specific rules aimed at assuring that minors’ opi-
nions should increasingly carry more weight in the final
decision” [29].
From indirect to direct benefit
A clinical trial on minors may be undertaken only if ben-
efit for this group of patients is obtained [13]. However,
it remains still open the question whether or not it is
acceptable to expose children to some research risks for
the benefit of others. The results of the survey conducted
by Wendler and Jenkins [30] support the acceptability of
such an exposure. According to Westra et al [31] the
absolute limit of minimal risks and minimal burdens sti-
pulated by the EU recommendations may prohibit
important appropriate research. The involvement of chil-
dren in research that will not directly benefit from them
clearly poses an ethical dilemma. To get a fair informed
assent/consent, the minor and his/her representative
should have also had a clear idea of the possible direct
effects [32] in accordance with the following ethical prin-
ciple that “patients’ interest should always prevail over
science/society” [33]. The clinical physician should con-
sider the patients and the trial NOT in a holistic way but
on a careful case-by-case assessment.
Risk threshold and legal risk
The application of the rules of good clinical practice when
performing clinical trials of drugs for human includes the
requirements for insurance policies safeguarding partici-
pants [2,13]. A more comprehensive approach to define
the risk among stakeholders is necessary. It could be
defined according to the type of research (medicinal pro-
ducts requiring a marketing authorization, post-marketing
studies, interventional or non-interventional clinical trials)
or to the type of trials (invasive, non-invasive, Phase I to
IV). Clinical trial monitoring according to a risk-based
approach would be more appropriate for off-patent pro-
ducts. It would entail a substantial reduction of workload
and cost, particularly for academic institutions that run
low-risk studies using marketed drugs [5,34]. To define the
legal risk of a clinical trial, insurance companies have a
more quantitative and simplified approach of the risk/ben-
efit assessment than scientists. The risk increases with the
number of patients involved in a trial and with the scope of
the coverage (e.g., as with innovative products). Usually,
contracts cover for a certain number of clinical trials con-
ducted by the same sponsor during a defined period of
time. Insurance companies are trying to reduce the com-
plexity of the risk assessment by selecting a set of specific
risk factors. As the data communicated by sponsors are
usually restricted for confidentiality reasons, this task is not
easy. Estimating the delay of the occurrence of a prejudice
(damage that may occur later on [35]) is another issue.
Knellwolf et al. Italian Journal of Pediatrics 2011, 37:12
http://www.ijponline.net/content/37/1/12
Page 3 of 6Ethical use of placebo
The placebo use is going to be accepted at regulatory
agency level in view of limiting the number of experi-
mental subject. Indeed, regulatory and ethical guidelines
highlight that in some instances the judicious use of pla-
cebo remains essential to demonstrate the efficiency of
new medicines (Table 1) [26,36,37]. Nevertheless, the
ethics of placebo-controlled paediatric studies causes
concern [10]. One of the reasons is that most paediatri-
cians/family doctors have no knowledge of drug trials
(methodological and ethical aspects). There is also a
poor awareness and understanding of paediatrics rando-
mized clinical trials by parents [16,38]. Placebo is how-
ever the standard control applied for efficient study
design such as added on and withdrawal design [10,37].
Ethics committee with paediatric expertise
A clinical trial on minors may be undertaken only if the
ethics committee has endorsed the protocol [26]. The
ethics committee which is an independent body includ-
ing health professionals must assess the relevance and
advantages of the clinical trial, the risk/benefit ratio, the
quality of the healthcare institution and whether the
research subjects (or their legal representatives) have
been properly informed. According to the recommenda-
tions of the ad hoc group, the ethics committee should
include paediatric experts such as physicians with pae-
diatric qualification, paediatric ethicists, and paediatric
pharmacologists. In addition the experts should demon-
strate at least some years of experience in paediatric
care and direct experience of clinical trials with children
in similar age groups [26]. Recruitment or co-option of
members with adequate experience seems non obvious
for some ethics committees as qualified researchers in
sufficient number are not available among EU-member-
states[25,39-41]. Newly emerging areas such as
paediatric research might face problematic workloads,
responsibilities and costs.
Heterogeneity of ethics committee procedures among
EU-member-states
In case of multicentre clinical trials carried out in more
than one member state simultaneously, an ethics
committee’s single opinion must be given for each EU-
member-state implicated with the multicentre trial [13].
E t h i c sc o m m i t t e e sa r eh e t e r o g e n e o u st h u so f f e r i n g
multiple views and judgments. Should be assessed local
features such as the quality of the investigation site,
appropriateness of the information document as formu-
lated in national language, issues connected to national
legislation (data protection, liability). Therefore, trials
could be delayed if they are to receive each local ethical
approval. Actually, clinical researchers get the impres-
sion of unnecessary duplication of efforts with multiple
ethics committees for the same trial. However, centrali-
zation or standardization may rationalize the application
process entailing that the final decision might be taken
without an in-depth consultation of people who are
directly involved in or aware of local ethical issues. And
regular communication with local ethics committees is
essential to guaranty the independence of the final deci-
sion and as a consequence the protection of vulnerable
subject. Yet these multiple consultations should not cre-
ate barriers or unnecessary delays [20,42,43]. An oppor-
tunity could be to nominate an ethics committee
coordinator/facilitator who should guaranty the quality
of the discussions between national ethics committees
having in mind the need for speed to get the final
approval. This ethics committee coordinator/facilitator
should not be an additional administrative step in the
evaluation process and should be ethically and econom-
ically independent from the sponsors of the study (may
b ear e p r e s e n t a t i v eo fo n eo ft h ei n v o l v e de t h i c s
committees).
ERA-NET Priomedchild final recommendations
The ERA-NET PRIOMEDCHILD final recommenda-
tions to facilitate the development of clinical research
with children are summarized in Table 2.
Conclusions
In order to move from “research as a potential damage”
to “research as health opportunity for children”
European paediatric research should change in a multi-
disciplinary approach, taking advantage of the 30-year
experience US approach. A better communication/
sensitization of parents concerning the necessity of clini-
cal research with a fair distribution of responsibilities
Table 1 Ethically acceptable use of Placebo
References Ethics of placebo-controlled trials
[36] When there is no commonly accepted therapy for the
condition and the new medical entity is the first one that
may modify the course of the disease.
[10] When patients have failed to respond to standard
treatment, they might be randomised to a new treatment
or a placebo because they have exhausted alternative
options
[36] When the commonly used therapy is of questionable
efficacy.
[36] When the commonly used therapy carries a high
frequency of undesirable side effects and the risks may be
significantly greater than the benefits.
[36] When the placebo is used to identify incidence and
severity of undesirable side effects produced by adding a
new treatment to an established regimen.
[36] When the disease process is characterized by frequent,
spontaneous exacerbations and remissions and the efficacy
of the therapy has not been demonstrated
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to participate in trials. Sufficient time to consider pros
and cons for child participation into a clinical trial
should be given to the family including the suggestion
to ask for external advice. To avoid supplementary
delays due to the necessity to submit the study to sev-
eral ethics committees the nomination of an indepen-
dent ethics coordinator should be an opportunity. Extra
funds, human resources, adequate research structures,
education and training are necessary to optimise the
process of implementing clinical trials with children.
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